Skip to Content

Teclistamab-cqyv (Tecvayli) in Combination with Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) for Relapsed Multiple Myeloma

Download PQI pdf

Last Updated: September 10, 2026

By: Radha Rohatgi, PharmD

About this PQI

The purpose of this document is to discuss the clinical considerations and general management of patients undergoing treatment with teclistamab-cqyv (teclistamab) and daratumumab and hyaluronidase-fihj (daratumumab) in relapsed or refractory multiple myeloma.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI